News - Generics
Generic Drugs Could Boost Pharmacies
8 February 2010
With some best-sellers due to go off-patent in coming years, generics could turn more profitable for the likes of CVS, Walgreen and Rite-Aid. ...
Click on the link to read the full article at Forbes (This link will open in a new window)Generic Drugs Could Boost Pharmacies
8 February 2010
With some best-sellers due to go off-patent in coming years, generics could turn more profitable for the likes of CVS, Walgreen and Rite-Aid. ...
Click on the link to read the full article at Forbes (This link will open in a new window)Generic Drugs Could Boost Pharmacies
8 February 2010
With some best-sellers due to go off-patent in coming years, generics could turn more profitable for the likes of CVS, Walgreen and Rite-Aid. ...
Click on the link to read the full article at Forbes (This link will open in a new window)Amneal Receives FDA Approval for Tramadol/APAP Tablets
8 February 2010
Amneal Pharmaceuticals LLC, headquartered in Hauppauge, NY is a US-based firm that develops, manufactures and distributes generic pharmaceuticals regulated ...
Click on the link to read the full article at MarketWatch (This link will open in a new window)Ratiopharm fields decisive takeover bids-sources
6 February 2010
That would make the deal the biggest generics takeover since Teva's $7.5 billion purchase of US rival Barr, announced in July 2008. The world's largest drug ...
Click on the link to read the full article at Reuters (This link will open in a new window)BUY OR SELL-Can Labopharm compete with generics?
5 February 2010
But worries persist over whether it can gain sales traction given that the US government's new healthcare reform proposed a switch to the cheaper generic ...
Click on the link to read the full article at Reuters (This link will open in a new window)Cephalon to buy generic firm Mepha for $590 mln
1 February 2010
O) said on Monday it will buy Mepha AG, the Swiss generic drugmaker owned by Germany's Merckle family, for about $590 million (622.5 million Swiss francs) ...
Click on the link to read the full article at Reuters (This link will open in a new window)Cephalon to buy generic firm Mepha for $590 mln
1 February 2010
O) said on Monday it will buy Mepha AG, the Swiss generic drugmaker owned by Germany's Merckle family, for about $590 million (622.5 million Swiss francs) ...
Click on the link to read the full article at Reuters (This link will open in a new window)Cephalon to buy generic firm Mepha for $590 mln
1 February 2010
O) said on Monday it will buy Mepha AG, the Swiss generic drugmaker owned by Germany's Merckle family, for about $590 million (622.5 million Swiss francs) ...
Click on the link to read the full article at Reuters (This link will open in a new window)Cephalon to buy generic firm Mepha for $590 mln
1 February 2010
O) said on Monday it will buy Mepha AG, the Swiss generic drugmaker owned by Germany's Merckle family, for about $590 million (622.5 million Swiss francs) ...
Click on the link to read the full article at Reuters (This link will open in a new window)Cephalon to buy generic firm Mepha for $590 mln
1 February 2010
O) said on Monday it will buy Mepha AG, the Swiss generic drugmaker owned by Germany's Merckle family, for about $590 million (622.5 million Swiss francs) ...
Click on the link to read the full article at Reuters (This link will open in a new window)
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
